JAZZ vs. VRTX: Jazz Pharmaceuticals vs. Vertex Pharmaceuticals Stock Comparison

Company Profile

Jazz Pharmaceuticals (JAZZ) and Vertex Pharmaceuticals (VRTX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while VRTX is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Vertex Pharmaceuticals (VRTX) at 20.80% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for VRTX.

Vertex Pharmaceuticals (VRTX) at 30.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.

Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Jazz Pharmaceuticals (JAZZ) reports EPS growth of -167.51%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Jazz Pharmaceuticals (JAZZ) at 1.82 and Vertex Pharmaceuticals (VRTX) at 2.34 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Vertex Pharmaceuticals (VRTX) at 0.31 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither Jazz Pharmaceuticals (JAZZ) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Jazz Pharmaceuticals (JAZZ) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Vertex Pharmaceuticals (VRTX) at 35.21 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Vertex Pharmaceuticals (VRTX) at 10.71 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Jazz Pharmaceuticals (JAZZ) at 3.59 is valued about in line with its industry on P/B ratio, while Vertex Pharmaceuticals (VRTX) at 6.63 carries an above-peer premium to book — VRTX is pricier on assets.

Valuation Metrics